Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3872580 | 0.84 | ADORA1 (0.58) | NPC1LMNAADORA2AADORA1KMT2A | |
| SCHEMBL4251467 | 0.77 | ABL1 (0.43) | ADORA2AADORA1 | |
| SCHEMBL4251648 | 0.76 | ADORA1 (0.46) | ADORA2AADORA1 | |
| SCHEMBL27728638 | 0.75 | ALDH1A1 (0.52) | ALDH1A1HPGDSMN1; SMN2NPC1POLB | |
| SCHEMBL4256692 | 0.74 | ADORA2A (0.39) | KDM4EADORA2AADORA1NPY5R | |
| SCHEMBL4256972 | 0.74 | ADORA1 (0.39) | ALDH1A1LMNAMAPTADORA2AADORA1 | |
| SCHEMBL4395277 | 0.73 | ALDH1A1 (0.55) | ALDH1A1HPGDSMN1; SMN2NPC1KDM4E | |
| SCHEMBL5124093 | 0.73 | ALDH1A1 (0.75) | ALDH1A1HPGDSMN1; SMN2NPC1POLB | |
| SCHEMBL29426144 | 0.72 | DYRK1A (0.46) | SMN1; SMN2NPC1POLBKDM4ELMNA | |
| SCHEMBL4251794 | 0.71 | KDM4E (0.39) | ALDH1A1HPGDSMN1; SMN2NPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598252-B2 | Compounds specific to adenosine A, receptors and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090082369-A1 | Pyrrolo[2,3d]pyrimidine compositions and their use | OSI PHARMACEUTICALS, INC. | 2009-03-26 | — | — | US | disclosed |
| EP-2011499-A2 | Pyrrolo[2,3d]Pyrimidine compositions and their use | OSI Pharmaceuticals, Inc. (US) | 2009-01-07 | — | — | EP | disclosed |
| US-7429574-B2 | 4-heterocyclo-pyrrolo[2,3d] pyrimidine compositions and their use | OSI PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-20080070936-A1 | Compounds specific to adenosine A1 receptors and uses thereof | OSI PHARMACEUTICALS, INC. | 2008-03-20 | — | — | US | disclosed |
| US-7160890-B2 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| US-20050043332-A1 | Pyrrolo[2,3d]pyrimidine compositions and their use | OSI PHARMACEUTICALS, INC. | 2005-02-24 | — | — | US | disclosed |
| US-6800633-B2 | CARDIOVASCULAR DISORDERS; NERVOUS SYSTEM DISORDERS | OSI PHARMACEUTICALS, INC. | 2004-10-05 | — | — | US | disclosed |
| US-20040082598-A1 | Compounds specific to adenosine A, receptors and uses thereof | OSI PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040082599-A1 | Compounds specific to adenosine A1 receptors and uses thereof | OSI PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-6680322-B2 | FOR THERAPY OF ASTHMA, ALLERGIC RHINITIS, RESPIRATORY SYSTEM DISORDERS | OSI PHARMACEUTICALS, INC. | 2004-01-20 | — | — | US | disclosed |
| US-6680324-B2 | 4-AMINO-6-PHENYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2004-01-20 | — | — | US | disclosed |
| US-6673802-B2 | CARDIOVASCULAR DISORDERS; CENTRAL NERVOUS SYSTEM DISORDERS | OSI PHARMACEUTICALS, INC. | 2004-01-06 | — | — | US | disclosed |
| US-6664252-B2 | (6-aryl-pyrrolo(2,3-d)pyrimidin-4-yl)amine derivatives; treating Parkinson's disease and diseases associated with locomotor activity, vasodilation, platelet inhibition, neutrophil superoxide generation, cognitive disorders, etc. | OSI PHARMACEUTICALS, INC. | 2003-12-16 | — | — | US | disclosed |
| US-20030073708-A1 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. | 2003-04-17 | — | — | US | disclosed |
| US-20030045536-A1 | Compounds specific to adenosine A1 receptors and uses thereof | OSI PHARMACEUTICALS, INC. | 2003-03-06 | — | — | US | disclosed |
| US-20030036545-A1 | Compounds specific to adenosine A2a receptor and uses thereof | OSI PHARMACEUTICALS, INC. | 2003-02-20 | — | — | US | disclosed |
| US-20020094974-A1 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. | 2002-07-18 | — | — | US | disclosed |
| US-20020058667-A1 | Compounds specific to adenosine A1 receptors and uses thereof | OSI PHARMACEUTICALS, INC. | 2002-05-16 | — | — | US | disclosed |
| US-20020028782-A1 | Pyrrolo [2, 3d] pyrimidine compositions and their use | OSI PHARMACEUTICALS, INC. | 2002-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073708-A1 | Compounds specific to adenosine A3 receptor and uses thereof | ADORA3, ADORA2A, ADORA1 | ALDH1A1 680/4885HPGD 1786/4885SMN1; SMN2 2072/4885 |
| US-20040082598-A1 | Compounds specific to adenosine A, receptors and uses thereof | ADORA2A, ADORA1, ADORA3 | ALDH1A1 585/4885HPGD 1623/4885SMN1; SMN2 2754/4885 |
| US-20020058667-A1 | Compounds specific to adenosine A1 receptors and uses thereof | ADORA1, ADORA2A, ADORA3 | ALDH1A1 311/4885HPGD 1512/4885SMN1; SMN2 2562/4885 |
| US-20030045536-A1 | Compounds specific to adenosine A1 receptors and uses thereof | ADORA1, ADORA2A, ADORA3 | ALDH1A1 311/4885HPGD 1512/4885SMN1; SMN2 2562/4885 |
| US-20090082369-A1 | Pyrrolo[2,3d]pyrimidine compositions and their use | ADORA3, ADORA2A, ADORA1 | ALDH1A1 1671/4885HPGD 2125/4885SMN1; SMN2 1272/4885 |
| US-20080070936-A1 | Compounds specific to adenosine A1 receptors and uses thereof | ADORA1, ADORA2A, ADORA3 | ALDH1A1 255/4885HPGD 1538/4885SMN1; SMN2 2057/4885 |
| US-20050043332-A1 | Pyrrolo[2,3d]pyrimidine compositions and their use | TYMP, UMPS, ADORA3 | ALDH1A1 1901/4885HPGD 671/4885SMN1; SMN2 3007/4885 |
| US-20020028782-A1 | Pyrrolo [2, 3d] pyrimidine compositions and their use | TYMP, UMPS, ADORA3 | ALDH1A1 1901/4885HPGD 671/4885SMN1; SMN2 3007/4885 |
| US-20030036545-A1 | Compounds specific to adenosine A2a receptor and uses thereof | ADORA2A, ADORA2B, ADORA3 | ALDH1A1 862/4885HPGD 1476/4885SMN1; SMN2 1552/4885 |
| US-20040082599-A1 | Compounds specific to adenosine A1 receptors and uses thereof | ADORA1, ADORA2A, ADORA3 | ALDH1A1 311/4885HPGD 1512/4885SMN1; SMN2 2562/4885 |
| US-20020094974-A1 | Compounds specific to adenosine A3 receptor and uses thereof | ADORA3, ADORA2A, ADORA1 | ALDH1A1 680/4885HPGD 1786/4885SMN1; SMN2 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.